Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Seattle Genetics and Icos sign agreement for the MAb component of SGN-15

Aug. 21, 2001

First clinical trial of rhuCD40L in cancer patients completed

Aug. 14, 2001

Phase I results reported for Merck KGaA's anti-EGF receptor MAb

Aug. 13, 2001

Lorus Therapeutics expands Virulizin clinical trial for pancreatic cancer

Aug. 9, 2001

FDA grants fast track status to TransMID-107R for the treatment of brain cancer

Aug. 8, 2001

Phase II trial planned for Aphton's antigastrin-targeted therapy in lung cancer patients

Aug. 6, 2001

Phase I/II trials evaluating PI-88 for cancer set to begin

Aug. 6, 2001

FDA accepts resubmission to the BLA for Zevalin

Aug. 6, 2001

Phase II trial of ABX-EGF for non-small cell lung cancer initiated

Aug. 3, 2001

Phase III trial for HspE7 for anal dysplasia caused by HPV completes enrollment ahead of schedule

Aug. 2, 2001

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...